Thrombocytopenia possibly induced by etretinate in a psoriatic patient.
A patient with psoriasis vulgaris developed multiple purpura on the extremities and hemorrhage at the oral mucosa and gingiva with marked thrombocytopenia. This thrombocytopenia was possibly induced by a retinoid agent, etretinate, from the clinical course and data. The total amount of etretinate administered was 2,410 mg over 191 days (41.9 mg/kg body weight, average 15.3 mg/day). A platelet transfusion partially restored the platelet count and the purpura and gingival hemorrhage disappeared approximately 10 days after the cessation of etretinate. However, the platelet count remains at 60-80 x 103/mm3 after two and a half years without etretinate therapy. Although there are only a few case reports of etretinate-induced thrombocytopenia, we should pay more attention to the peripheral platelet count during etretinate therapy.
Seishima
Mariko
M
Department of Dermatology, Ogaki Municipal Hospital, Minaminokawa-cho 4-86, Ogaki City, 503-8502, Japan.
Oda
Makiko
M
Yamanaka
Shinya
S
D000368:Aged; D005050:Etretinate / Q000009:adverse effects*; D006801:Humans; D007641:Keratolytic Agents / Q000009:adverse effects*; D008297:Male; D011565:Psoriasis / Q000188:drug therapy; D013921:Thrombocytopenia / Q000139:chemically induced*
D007641:Keratolytic Agents; D005050:Etretinate